A Phase III, randomized, double-blind, placebo-controlled study to assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with Bronchiectasis (The AIRTIVITY® Study)

162991397-0014OpenA Phase III, randomized, double-blind, placebo-controlled study to assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with Bronchiectasis (The AIRTIVITY® Study)NCT06872892IndustrialAdultTreatmentIIIOtherO'Donnell, AnneGeorgetown University Medical Center : Amen Hamed; Lombardi Comprehensive Cancer Center : Amen HamedGUMC Medicine Pulmonary9081Amen HamedAmen Hamedamen.m.hamed@gunet.georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>